1
|
Tomita Y, Motzer RJ, Choueiri TK, Rini BI, Miyake H, Uemura H, Albiges L, Fujii Y, Umeyama Y, Wang J, Mariani M, Schmidinger M. Efficacy and safety of avelumab plus axitinib in elderly patients with advanced renal cell carcinoma: extended follow-up results from JAVELIN Renal 101. ESMO Open 2022; 7:100450. [PMID: 35397432 PMCID: PMC9058903 DOI: 10.1016/j.esmoop.2022.100450] [Citation(s) in RCA: 15] [Impact Index Per Article: 7.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/02/2021] [Revised: 02/06/2022] [Accepted: 02/16/2022] [Indexed: 11/12/2022] Open
Abstract
Background In the phase III JAVELIN Renal 101 trial, first-line avelumab plus axitinib demonstrated a progression-free survival (PFS) and objective response rate (ORR) benefit versus sunitinib in patients with advanced renal cell carcinoma (aRCC). However, efficacy in elderly patients remains unclear. We report efficacy and safety by age group from the second interim analysis of overall survival (OS). Patients and methods PFS and ORR as per blinded independent central review (RECIST 1.1), OS, and safety were assessed in patient groups aged <65, ≥65 to <75, and ≥75 years. Results In the avelumab plus axitinib and sunitinib arms, 271/138/33 and 275/128/41 patients aged <65, ≥65 to <75, and ≥75 years, respectively, were randomized. At data cut-off (January 2019), median PFS [95% confidence interval (CI)] with avelumab plus axitinib versus sunitinib in these respective age groups was 11.6 (8.4-19.4) versus 6.9 (5.6-8.4) months [hazard ratio (HR), 0.63; 95% CI 0.501-0.786], 13.8 (11.1-18.0) versus 11.0 (7.8-16.6) months (HR, 0.88; 95% CI 0.627-1.231), and 13.8 [7.0-not estimable (NE)] versus 9.8 (4.3-NE) months (HR, 0.76; 95% CI 0.378-1.511). Median OS (95% CI) in the respective age groups was not reached (NR) (NE-NE) versus 28.6 (25.5-NE) months (HR, 0.74; 95% CI 0.541-1.022), 30.0 (30.0-NE) versus NR (NE-NE) months (HR, 0.89; 95% CI 0.546-1.467), and 25.3 (19.9-NE) versus NR (19.4-NE) months (HR, 0.87; 95% CI 0.359-2.106). ORR (95% CI) in the respective age groups was 49.4% (43.3% to 55.6%) versus 27.3% (22.1% to 32.9%), 60.9% (52.2% to 69.1%) versus 28.9% (21.2% to 37.6%), and 42.4% (25.5% to 60.8%) versus 22.0% (10.6% to 37.6%). In the avelumab plus axitinib arm, grade ≥3 adverse events (AEs) and immune-related AEs occurred in 76.9%/81.2%/72.7% and 45.5%/48.1%/36.4% in the respective age groups. Conclusions First-line avelumab plus axitinib demonstrated favorable efficacy across age groups, including patients aged ≥75 years. OS data were still immature; follow-up is ongoing. The safety profile was generally consistent across age groups. Elderly patients experience a decline in immune activity that might affect response to immunotherapy. We evaluated avelumab plus axitinib versus sunitinib by age group in patients with aRCC. Avelumab plus axitinib had favorable efficacy versus sunitinib across age groups, including patients aged ≥75 years. The safety profile was generally consistent among age groups treated with avelumab plus axitinib or sunitinib.
Collapse
Affiliation(s)
- Y Tomita
- Department of Urology, Niigata University Graduate School of Medicine, Niigata, Japan; Department of Molecular Oncology, Niigata University Graduate School of Medicine, Niigata, Japan.
| | - R J Motzer
- Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, USA
| | - T K Choueiri
- The Lank Center for Genitourinary Oncology, Dana-Farber Cancer Institute, Boston, USA
| | - B I Rini
- Department of Hematology and Medical Oncology, Vanderbilt University, Nashville, USA
| | - H Miyake
- Department of Urology, Hamamatsu University School of Medicine, Hamamatsu, Japan
| | - H Uemura
- Department of Urology, Faculty of Medicine, Kindai University, Osaka, Japan
| | - L Albiges
- Department of Cancer Medicine, Institut Gustave Roussy, Villejuif, France
| | - Y Fujii
- Pfizer R&D Japan, Tokyo, Japan
| | | | | | | | - M Schmidinger
- Department of Urology, Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria
| |
Collapse
|
2
|
Fujita K, Matsushita M, Motooka D, Hatano K, Nishimoto M, Banno E, Hata J, Tsujimura A, Nakamura S, Minami T, Nozawa M, Yoshimura K, Obara W, Uemura H, Nonomura N. Firmicutes in gut microbiota correlate with blood testosterone levels in elderly men. Eur Urol 2022. [DOI: 10.1016/s0302-2838(22)00479-1] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022]
|
3
|
Takezawa K, Fujita K, Matsushita M, Motooka D, Hatano K, Banno E, Shimizu N, Takao T, Takada S, Okada K, Fukuhara S, Kiuchi H, Uemura H, Nakamura S, Kojima Y, Nonomura N. The association between human gut microbiota and prostate enlargement. Eur Urol 2022. [DOI: 10.1016/s0302-2838(22)00673-x] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/04/2022]
|
4
|
Azad A, Chua M, Smith M, Chi K, Small E, Agarwal N, Uemura H, Uemura H, Chung B, Bhaumik A, Brookman-May S, Rooney B, Mc Carthy S, De Porre P, Chowdhury S. Exploratory analyses of incidence of skin rash and efficacy with apalutamide (APA) treatment of patients (pts) with advanced prostate cancer in SPARTAN and TITAN studies. EUR UROL SUPPL 2021. [DOI: 10.1016/s2666-1683(21)03140-2] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022] Open
|
5
|
Chung B, Huang J, Uemura H, Choi Y, Ye Z, Suzuki H, Kang T, He D, Joung J, Brookman-May S, McCarthy S, Bhaumik A, He J, Mundle S, Chowdhury S, Agarwal N, Ye D, Chi K, Uemura H. 608P Apalutamide (APA) efficacy and safety in Asian patients with metastatic castration-sensitive prostate cancer (mCSPC). Ann Oncol 2021. [DOI: 10.1016/j.annonc.2021.08.1121] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/20/2022] Open
|
6
|
Kobayashi K, Okuno N, Arai G, Nakatsu H, Maniwa A, Kamiya N, Satoh T, Kikukawa H, Nasu Y, Uemura H, Nakashima T, Mikami K, Iinuma M, Tanabe K, Furukawa J, Kobayashi H. Efficacy and safety of abiraterone acetate plus prednisolone in patients with early metastatic castration-resistant prostate cancer who failed first-line androgen-deprivation therapy: a single-arm, phase 4 study. Jpn J Clin Oncol 2021; 51:544-551. [PMID: 33324967 PMCID: PMC8012350 DOI: 10.1093/jjco/hyaa225] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/01/2020] [Accepted: 10/27/2020] [Indexed: 12/24/2022] Open
Abstract
Aim The aim was to evaluate the efficacy and safety of abiraterone acetate plus prednisolone in patients with chemotherapy-naïve early metastatic castration-resistant prostate cancer who failed first-line androgen deprivation therapy. Methods Patients with early metastatic castration-resistant prostate cancer with confirmed prostate-specific antigen progression within 1-year or prostate-specific antigen progression without having normal prostate-specific antigen level (<4.0 ng/mL) during first-line androgen deprivation therapy were enrolled and administered abiraterone acetate (1000 mg) plus prednisolone (10 mg). A minimum of 48 patients were required according to Simon’s minimax design. The primary endpoint was prostate-specific antigen response rate (≥50% prostate-specific antigen decline by 12 weeks), secondary endpoints included prostate-specific antigen progression-free survival and overall survival. Safety parameters were also assessed. Results For efficacy, 49/50 patients were evaluable. Median age was 73 (range: 55–86) years. The median duration of initial androgen deprivation therapy was 32.4 (range: 13.4–84.1) weeks and 48 patients experienced prostate-specific antigen progression within 1-year after initiation of androgen deprivation therapy. prostate-specific antigen response rate was 55.1% (95% confidence interval: 40.2%–69.3%), median prostate-specific antigen–progression-free survival was 24.1 weeks, and median overall survival was 102.9 weeks (95% confidence interval: 64.86 not estimable [NE]). Most common adverse event was nasopharyngitis (15/50 patients, 30.0%). The most common ≥grade 3 adverse event was alanine aminotransferase increased (6/50 patients, 12.0%). Conclusions Abiraterone acetate plus prednisolone demonstrated a high prostate-specific antigen response rate of 55.1%, suggesting tumor growth still depends on androgen synthesis in patients with early metastatic castration-resistant prostate cancer. However, prostate-specific antigen–progression-free survival was shorter than that reported in previous studies. Considering the benefit–risk profile, abiraterone acetate plus prednisolone would be a beneficial treatment option for patients with chemotherapy-naive metastatic prostate cancer who show early castration resistance.
Collapse
Affiliation(s)
- K Kobayashi
- Department of Urology, Federation of National Public Service Personnel Mutual Aid Associations Yokosuka Kyosai Hospital, Kanagawa, Japan
| | - N Okuno
- Department of Urology, Independent Administrative Institution National Hospital Organization Sagamihara Hospital, Kanagawa, Japan
| | - G Arai
- Department of Urology, Dokkyo Medical University Saitama Medical Center, Saitama, Japan
| | - H Nakatsu
- Department of Urology, Asahi General Hospital, Chiba, Japan
| | - A Maniwa
- Department of Urology, Independent Administrative Institution National Hospital Organization Shizuoka Medical Center, Shizuoka, Japan
| | - N Kamiya
- Department of Urology, Toho University Sakura Medical Center, Chiba, Japan
| | - T Satoh
- Department of Urology, Kitasato University School of Medicine, Kanagawa, Japan
| | - H Kikukawa
- Department of Urology, Independent Administrative Institution National Hospital Organization Kumamoto Medical Center, Kumamoto, Japan
| | - Y Nasu
- Department of Urology, Japan Organization of Occupational Health and Safety Okayama Rosai Hospital, Okayama, Japan
| | - H Uemura
- Department of Urology and Renal Transplantation, Yokohama City University Medical Center, Kanagawa, Japan
| | - T Nakashima
- Department of Urology, Ishikawa Prefectural Central Hospital, Ishikawa, Japan
| | - K Mikami
- Department of Urology, Chibaken Saiseikai Narashino Hospital, Chiba, Japan
| | - M Iinuma
- Department of Urology, Independent Administrative Institution National Hospital Organization Mito Medical Center, Ibaraki, Japan
| | - K Tanabe
- Department of Urology, Tokyo Women's Medical University Hospital, Tokyo, Japan
| | - J Furukawa
- Department of Urology, National University Corporation Kobe University Hospital, Hyogo, Japan
| | | |
Collapse
|
7
|
Uemura H, Lee J, Oudard S, Hadaschik B, Saad F, Cella D, Basch E, Graff J, Dibaj S, Li S, Brookman-May S, De Porre P, Bevans K, Trudeau J, Smith M, Small E. 221P Patient-reported sexual and urinary function in nonmetastatic castration-resistant prostate cancer (nmCRPC) when treated with apalutamide (APA) vs placebo (PBO) and ongoing androgen deprivation therapy (ADT) in SPARTAN. Ann Oncol 2020. [DOI: 10.1016/j.annonc.2020.10.441] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/22/2022] Open
|
8
|
Tsuzuki T, Ohe C, Osawa T, Yasuda Y, Tanaka T, Anai S, Yamana K, Hatakeyama S, Yoshimoto T, Nakagawa Y, Fukuyama T, Matsubara N, Kimura G, Uemura H. 725P Prognostic values of PD-L1 expression and CD8 infiltration phenotype in metastatic and recurrent renal cell carcinoma: An exploratory analysis of the ARCHERY study. Ann Oncol 2020. [DOI: 10.1016/j.annonc.2020.08.797] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022] Open
|
9
|
Muraguchi N, Uemura H, Kubota C. 222 Effective donor selection before superovulation treatment for Japanese Black beef cattle. Reprod Fertil Dev 2020. [DOI: 10.1071/rdv32n2ab222] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/23/2022] Open
Abstract
Japanese Black beef cattle (JBBC) are a leading Wagyu breed in Japan. Embryo transfers are being used to improve JBBC, a sturdy, fast-maturing breed prized for its marbled beef; however, relevant donor selection techniques have not been fully established. Accordingly, in this study, in order to produce embryos efficiently, we aimed to investigate donor selection techniques based on follicle counts at different time points (Experiment 1) and an associated genetic marker (Experiment 2). Statistical differences were evaluated with Student's t-test or Welch's t-test, regarding P<0.05 as significant. In Experiment 1, we initially targeted 57 JBBCs for evaluation. Their follicle counts were determined by ultrasound 3 days before the start of superovulation (pre), close to the time of follicular wave emergence, and they were grouped according to number of follicles (0-19, 20-29, 30-39, and ≥40). Each cow was administered a tapered dose of FSH-R (20 AU) for superovulation, and then subjected to AI with cryopreserved semen from bulls of proven fecundity. Embryos were collected 7 days after AI by non-surgical intrauterine reflux. Post-AI follicle counts were done before ovulation and did not differ significantly from pre-superovulation follicle count in any group (range: −1.09 to 0.61). We then targeted a further 12 JBBC undergoing superovulation and AI with the same procedures, for counting of follicles at 30 days before (Day −30) embryo recovery (ER), pre-superovulation, and AI, and counting of corpora lutea and large follicles at ER, to investigate correlations between counts. We used decision coefficient (R2), regarding R2 ≥ 0.5 as significant. We found positive correlations (R2) at Day −30 with pre-superovulation (0.91), AI (0.63), and ER (0.63), and at pre-superovulation with AI (0.69) and ER (0.74). In Experiment 2, we targeted 69 JBBCs for detection of mutations in the GRIA1 gene, which encodes inotropic glutamate receptor AMPA1 with a known association with ovulation rate, and embryo yield measurements. DNA obtained from blood was subject to microsatellite polymorphism analysis, for mutations at base 917 of GRIA1 exon 7. We identified 33 cows (48%) as bearers of the wild-type allele (GG), 29 cows (42%) as bearers of the heterozygous mutation (GA), and seven cows (10%) as bearers of the homozygous mutation (AA). Average embryo yield was highest in wild-type cows, followed by heterozygous mutants and then homozygous mutants, and was significantly lower for homozygous mutants than for the other two types. Our study results demonstrated that follicle count before superovulation and GRIA1 gene analysis have utility for selecting donors for embryo transfer in JBBC. Furthermore, follicle counts at the early time point of 30 days before ER can be a useful indicator for this selection.
Collapse
|
10
|
Chung B, McQuarrie K, Bjartell A, Chowdhury S, Pereira de Santana Gomes A, Özgüroğlu M, Juárez Soto Á, Merseburger A, Uemura H, Ye D, Given R, Miladinovic B, Li N, Hudgens S, Floden L, Lopez-Gitlitz A, Chi K, Agarwal N. Apalutamide (APA) plus androgen deprivation therapy (ADT) for metastatic castration-sensitive prostate cancer (mCSPC): Analysis of pain and fatigue in the TITAN study. Ann Oncol 2019. [DOI: 10.1093/annonc/mdz424] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
11
|
Small EJ, Saad F, Chowdhury S, Oudard S, Hadaschik BA, Graff JN, Olmos D, Mainwaring PN, Lee JY, Uemura H, De Porre P, Smith AA, Zhang K, Lopez-Gitlitz A, Smith MR. Apalutamide and overall survival in non-metastatic castration-resistant prostate cancer. Ann Oncol 2019; 30:1813-1820. [PMID: 31560066 PMCID: PMC6927320 DOI: 10.1093/annonc/mdz397] [Citation(s) in RCA: 79] [Impact Index Per Article: 15.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/20/2022] Open
Abstract
BACKGROUND In the SPARTAN study, compared with placebo, apalutamide added to ongoing androgen deprivation therapy significantly prolonged metastasis-free survival (MFS) and time to symptomatic progression in patients with high-risk non-metastatic castration-resistant prostate cancer (nmCRPC). Overall survival (OS) results at the first interim analysis (IA1) were immature, with 104 of 427 (24%) events required for planned final OS analysis. Here, we report the results of a second pre-specified interim analysis (IA2). METHODS One thousand two hundred and seven patients with nmCRPC were randomized 2 : 1 to apalutamide (240 mg daily) or placebo. The primary end point of the study was MFS. Subsequent therapy for metastatic CRPC was permitted. When the primary end point was met, the study was unblinded. Patients receiving placebo who had not yet developed metastases were offered open-label apalutamide. At IA2, pre-specified analysis of OS was undertaken, using a group-sequential testing procedure with O'Brien-Fleming-type alpha spending function. Safety and second progression-free survival (PFS2) were assessed. RESULTS Median follow-up was 41 months. With 285 (67% of required) OS events, apalutamide was associated with an improved OS compared with placebo (HR 0.75; 95% CI 0.59-0.96; P = 0.0197), although the P-value did not cross the pre-specified O'Brien-Fleming boundary of 0.0121. Apalutamide improved PFS2 (HR 0.55; 95% CI 0.45-0.68). At IA2, 69% of placebo-treated and 40% of apalutamide-treated patients had received subsequent life-prolonging therapy for metastatic CRPC. No new safety signals were observed. CONCLUSION In patients with nmCRPC, apalutamide was associated with a 25% reduction in risk of death compared with placebo. This OS benefit was observed despite crossover of placebo-treated patients and higher rates of subsequent life-prolonging therapy for the placebo group.
Collapse
Affiliation(s)
- E J Small
- Helen Diller Family Comprehensive Cancer Center, University of California San Francisco, San Francisco, CA, USA.
| | - F Saad
- Centre Hospitalier de l'Université de Montréal, Université de Montréal, Montréal, QC, Canada
| | - S Chowdhury
- Guy's, King's and St. Thomas' Hospitals, London; Sarah Cannon Research Institute, London, UK
| | - S Oudard
- Georges Pompidou Hospital, University René Descartes, Paris, France
| | - B A Hadaschik
- University of Duisburg-Essen, Essen; Ruprecht-Karls University Heidelberg, Heidelberg, Germany
| | - J N Graff
- VA Portland Health Care System, Portland; Knight Cancer Institute, Oregon Health & Science University, Portland, OR, USA
| | - D Olmos
- Spanish National Cancer Research Centre (CNIO), Madrid; Hospitales Universitarios Virgen de la Victoria y Regional, Institute of Biomedical Research in Málaga (IBIMA), Málaga, Spain
| | - P N Mainwaring
- Centre for Personalized Nanomedicine, University of Queensland, Brisbane, Australia
| | - J Y Lee
- St. Mary's Hospital of Catholic University, Seoul, South Korea
| | - H Uemura
- Yokohama City University Medical Center, Yokohama, Japan
| | - P De Porre
- Janssen Research & Development, Beerse, Belgium
| | - A A Smith
- Janssen Research & Development, Spring House, PA
| | - K Zhang
- Janssen Research & Development, San Diego, CA
| | | | - M R Smith
- Massachusetts General Hospital Cancer Center, Boston, MA; Harvard Medical School, Boston, MA, USA
| |
Collapse
|
12
|
Smith M, Saad F, Chowdhury S, Oudard S, Hadaschik B, Graff J, Olmos D, Mainwaring P, Lee J, Uemura H, De Porre P, Smith A, Zhang K, Lopez-Gitlitz A, Small E. Apalutamide (APA) and overall survival (OS) in patients (pts) with nonmetastatic castration-resistant prostate cancer (nmCRPC): Updated results from the phase III SPARTAN study. Ann Oncol 2019. [DOI: 10.1093/annonc/mdz248] [Citation(s) in RCA: 6] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
13
|
Agarwal N, McQuarrie K, Bjartell A, Chowdhury S, Gomes AJPDS, Chung B, Özgüroğlu M, Soto ÁJ, Merseburger A, Uemura H, Ye D, Given R, Miladinovic B, Dearden L, Deprince K, Naini V, Lopez-Gitlitz A, Chi K. Patient-reported outcomes (PROs) from TITAN: A phase III, randomized, double-blind study of apalutamide (APA) versus placebo (PBO) added to androgen deprivation therapy (ADT) in patients (pts) with metastatic castration-sensitive prostate cancer (mCSPC). Ann Oncol 2019. [DOI: 10.1093/annonc/mdz248.008] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022] Open
|
14
|
Uemura M, Tomita Y, Miyake H, Hatakeyama S, Kanayama HO, Numakura K, Takagi T, Kato T, Eto M, Obara W, Uemura H, Motzer R, Fujii Y, Kamei Y, Oya M. Randomized phase III trial of avelumab + axitinib vs sunitinib as first-line treatment for advanced renal cell carcinoma: JAVELIN renal 101 Japanese subgroup analysis. Ann Oncol 2019. [DOI: 10.1093/annonc/mdz249.052] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
15
|
Kanesvaran R, Uemura H, Ye D, Chiong E, Lojanapiwat B, Pu YS, Kumar Rawal S, Razack A, Zeng H, Chung B, Tsai YS, Noor Ashani M, Liu Y, Asinas-Tan M, Liu W, Low G, van Kooten Losio M. United in Fight against prOstate cancer registry (UFO): Treatment patterns and quality of life from a large, multi-center, longitudinal cohort study in Asia. Ann Oncol 2018. [DOI: 10.1093/annonc/mdy434] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
16
|
Mainwaring P, Small E, Uemura H, Lee J, Pang ST, Marx G, Kwon T, Satoh T, Bhaumik A, Cheng S, Londhe A, Lopez-Gitlitz A, Smith M. Efficacy and safety of apalutamide (APA) in patients (pts) with nonmetastatic castration-resistant prostate cancer (nmCRPC) from SPARTAN: Asian subpopulation. Ann Oncol 2018. [DOI: 10.1093/annonc/mdy434.001] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
17
|
Mochizuki T, Teranishi J, Takamoto D, Ohtaka M, Kawahara T, Makiyama K, Uemura H. Long-term Survival in a Kidney Transplantation Patient With Progressive Multifocal Leukoencephalopathy: A Case Report. Transplant Proc 2018; 50:2558-2561. [PMID: 30316398 DOI: 10.1016/j.transproceed.2018.02.194] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/12/2018] [Accepted: 02/19/2018] [Indexed: 11/13/2022]
Abstract
Post-kidney transplantation progressive multifocal leukoencephalopathy (PML) is a rare disease on which there are very few published reports on record. PML is a demyelinating disease caused by a destructive infection of the oligodendrocytes by the JC polyomavirus. No effective therapeutic protocol has been established other than measures to revive the immune function by reducing or discontinuing the administration of immunosuppressive agents. Most cases are progressive and show a poor prognosis. We herein report a case in which renal function has been maintained for 2 years following the onset of PML, which was initially diagnosed 3 years after kidney transplantation.
Collapse
Affiliation(s)
- T Mochizuki
- Department of Urology and Renal Transplantation, Yokohama City University Medical Center, Yokohama, Japan.
| | - J Teranishi
- Department of Urology and Renal Transplantation, Yokohama City University Medical Center, Yokohama, Japan
| | - D Takamoto
- Department of Urology and Renal Transplantation, Yokohama City University Medical Center, Yokohama, Japan
| | - M Ohtaka
- Department of Urology and Renal Transplantation, Yokohama City University Medical Center, Yokohama, Japan
| | - T Kawahara
- Department of Urology and Renal Transplantation, Yokohama City University Medical Center, Yokohama, Japan
| | - K Makiyama
- Department of Urology, Yokohama City University School of Medicine, Yokohama, Japan
| | - H Uemura
- Department of Urology and Renal Transplantation, Yokohama City University Medical Center, Yokohama, Japan
| |
Collapse
|
18
|
Small E, Cella D, McQuarrie K, Saad F, Hadaschik B, Graff J, Uemura H, Oudard S, Yu M, Hudgens S, Lopez-Gitlitz A, Rooney B, Morris M, Smith M. Health-related quality of life (HRQoL) after progressive disease (PD) in SPARTAN: A phase III trial of apalutamide (APA) versus placebo (PBO) in men with nonmetastatic castration-resistant prostate cancer (nmCRPC). Ann Oncol 2018. [DOI: 10.1093/annonc/mdy284.013] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
|
19
|
Smith M, Perez-Ruixo C, Ackaert O, Ouellet D, Chien C, Uemura H, Olmos D, Mainwaring P, Lee J, Yu M, Perez-Ruixo JJ, Small E. Relationship between apalutamide (APA) exposure and metastasis-free survival (MFS) in patients (pts) with nonmetastatic castration-resistant prostate cancer (nmCRPC) from SPARTAN. Ann Oncol 2018. [DOI: 10.1093/annonc/mdy284.015] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
20
|
Uemura H, Ye D, Kanesvaran R, Zeng H, Pu YS, Chiong E, Lojanapiwat B, Rawal S, Chung B, Razack A, Tsai YS, Liu Y, Asinas-Tan M, Liu W, Low G, van Kooten Losio M. United in fight against prostate cancer registry (UFO): First results from a large, multi-center, prospective, longitudinal cohort study in Asia. Ann Oncol 2018. [DOI: 10.1093/annonc/mdy284.066] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
21
|
Takamoto D, Kawahara T, Mochizuki T, Makiyama K, Teranishi J, Uemura H. A Longer History of Hemodialysis Can Lead to Sarcopenia in Renal Transplantation Patients. Transplant Proc 2018; 50:2447-2450. [DOI: 10.1016/j.transproceed.2018.02.192] [Citation(s) in RCA: 9] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/09/2018] [Accepted: 02/26/2018] [Indexed: 12/20/2022]
|
22
|
Shimanoe C, Hachiya T, Hara M, Nishida Y, Tanaka K, Sutoh Y, Shimizu A, Hishida A, Kawai S, Okada R, Tamura T, Matsuo K, Ito H, Ozaki E, Matsui D, Ibusuki R, Shimoshikiryo I, Takashima N, Kadota A, Arisawa K, Uemura H, Suzuki S, Watanabe M, Kuriki K, Endoh K, Mikami H, Nakamura Y, Momozawa Y, Kubo M, Nakatochi M, Naito M, Wakai K. A genome-wide association study of coping behaviors suggests FBXO45
is associated with emotional expression. Genes, Brain and Behavior 2018; 18:e12481. [DOI: 10.1111/gbb.12481] [Citation(s) in RCA: 12] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Subscribe] [Scholar Register] [Received: 10/23/2017] [Revised: 03/15/2018] [Accepted: 04/11/2018] [Indexed: 12/20/2022]
Affiliation(s)
- C. Shimanoe
- Department of Preventive Medicine, Faculty of Medicine; Saga University; Saga Japan
| | - T. Hachiya
- Division of Biomedical Information Analysis, Iwate Tohoku Medical Megabank Organization; Disaster Reconstruction Center, Iwate Medical University; Iwate Japan
| | - M. Hara
- Department of Preventive Medicine, Faculty of Medicine; Saga University; Saga Japan
| | - Y. Nishida
- Department of Preventive Medicine, Faculty of Medicine; Saga University; Saga Japan
| | - K. Tanaka
- Department of Preventive Medicine, Faculty of Medicine; Saga University; Saga Japan
| | - Y. Sutoh
- Division of Biomedical Information Analysis, Iwate Tohoku Medical Megabank Organization; Disaster Reconstruction Center, Iwate Medical University; Iwate Japan
| | - A. Shimizu
- Division of Biomedical Information Analysis, Iwate Tohoku Medical Megabank Organization; Disaster Reconstruction Center, Iwate Medical University; Iwate Japan
| | - A. Hishida
- Department of Preventive Medicine; Nagoya University Graduate School of Medicine; Nagoya Japan
| | - S. Kawai
- Department of Preventive Medicine; Nagoya University Graduate School of Medicine; Nagoya Japan
| | - R. Okada
- Department of Preventive Medicine; Nagoya University Graduate School of Medicine; Nagoya Japan
| | - T. Tamura
- Department of Preventive Medicine; Nagoya University Graduate School of Medicine; Nagoya Japan
| | - K. Matsuo
- Division of Molecular and Clinical Epidemiology; Aichi Cancer Center Research Institute; Nagoya Japan
| | - H. Ito
- Division of Molecular and Clinical Epidemiology; Aichi Cancer Center Research Institute; Nagoya Japan
| | - E. Ozaki
- Department of Epidemiology for Community Health and Medicine; Kyoto Prefectural University of Medicine; Kyoto Japan
| | - D. Matsui
- Department of Epidemiology for Community Health and Medicine; Kyoto Prefectural University of Medicine; Kyoto Japan
| | - R. Ibusuki
- Department of International Island and Community Medicine; Kagoshima University Graduate School of Medical and Dental Sciences; Kagoshima Japan
| | - I. Shimoshikiryo
- Department of International Island and Community Medicine; Kagoshima University Graduate School of Medical and Dental Sciences; Kagoshima Japan
| | - N. Takashima
- Department of Public Health; Shiga University of Medical Science; Otsu Japan
| | - A. Kadota
- Department of Public Health; Shiga University of Medical Science; Otsu Japan
- Center for Epidemiologic Research in Asia; Shiga University of Medical Science; Otsu Japan
| | - K. Arisawa
- Department of Preventive Medicine; Institute of Biomedical Sciences, Tokushima University Graduate School; Tokushima Japan
| | - H. Uemura
- Department of Preventive Medicine; Institute of Biomedical Sciences, Tokushima University Graduate School; Tokushima Japan
| | - S. Suzuki
- Department of Public Health; Nagoya City University Graduate School of Medical Sciences; Nagoya Japan
| | - M. Watanabe
- Department of Public Health; Nagoya City University Graduate School of Medical Sciences; Nagoya Japan
| | - K. Kuriki
- Laboratory of Public Health, Division of Nutritional Sciences, School of Food and Nutritional Sciences; University of Shizuoka; Shizuoka Japan
| | - K. Endoh
- Laboratory of Public Health, Division of Nutritional Sciences, School of Food and Nutritional Sciences; University of Shizuoka; Shizuoka Japan
| | - H. Mikami
- Division of Cancer Prevention and Epidemiology; Chiba Cancer Center; Chiba Japan
| | - Y. Nakamura
- Division of Cancer Prevention and Epidemiology; Chiba Cancer Center; Chiba Japan
| | - Y. Momozawa
- Laboratory for Genotyping Development; RIKEN Center for Integrative Medical Sciences; Yokohama Japan
| | - M. Kubo
- RIKEN Center for Integrative Medical Sciences; Yokohama Japan
| | - M. Nakatochi
- Statistical Analysis Section; Center for Advanced Medicine and Clinical Research, Nagoya University Hospital; Nagoya Japan
| | - M. Naito
- Department of Maxillofacial Functional Development; Graduate School of Biomedical and Health Sciences, Hiroshima University; Hiroshima Japan
| | - K. Wakai
- Department of Preventive Medicine; Nagoya University Graduate School of Medicine; Nagoya Japan
| |
Collapse
|
23
|
Kondo T, Kuroda S, Usui K, Mori K, Asai T, Takeshima T, Kawahara T, Hamanoue H, Uemura H, Yumura Y. A case of a rare variant of Klinefelter syndrome, 47,XY,i(X)(q10). Andrologia 2018; 50:e13024. [PMID: 29665107 DOI: 10.1111/and.13024] [Citation(s) in RCA: 7] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 03/08/2018] [Indexed: 11/28/2022] Open
Abstract
Klinefelter syndrome is a condition in which a male patient has one Y chromosome and one or more extra X chromosomes. It is the most common sex chromosome disorder. Klinefelter syndrome is distinguished by many clinical features, such as infertility, high gonadotropin and low testosterone levels, increased height, and sparse body and facial hair. We report the case of a 32-year-old man who visited our hospital complaining of male infertility. Semen analysis showed azoospermia, and chromosomal analysis revealed a 47,XY,i(X)(q10) karyotype, which is a rare variant of Klinefelter syndrome. No spermatozoon was found on microdissection testicular sperm extraction, and the testis biopsy histology showed only Sertoli cells and hyalinised seminiferous tubules. 47,XY, i(X)(q10) has an additional isochromosome made of the long arm of the X chromosome, which shares some features of classical Klinefelter syndrome in many aspects, but patients are usually shorter than average height and have normal intelligence. In addition, to the best of our knowledge, no successful sperm extractions from 47,XY, i(X)(q10) patients were reported in the literature. The reports of patients who have undergone microdissection testicular sperm extraction are very rare. Further reports and studies of this chromosomal abnormality are needed.
Collapse
Affiliation(s)
- T Kondo
- Department of Urology, Reproduction Center, Yokohama City University Medical Center, Yokohama, Japan
| | - S Kuroda
- Department of Urology, Reproduction Center, Yokohama City University Medical Center, Yokohama, Japan
| | - K Usui
- Department of Urology, Reproduction Center, Yokohama City University Medical Center, Yokohama, Japan
| | - K Mori
- Department of Urology, Reproduction Center, Yokohama City University Medical Center, Yokohama, Japan
| | - T Asai
- Department of Urology, Reproduction Center, Yokohama City University Medical Center, Yokohama, Japan
| | - T Takeshima
- Department of Urology, Reproduction Center, Yokohama City University Medical Center, Yokohama, Japan
| | - T Kawahara
- Department of Urology and Renal Transplantation, Yokohama City University Medical Center, Yokohama, Japan
| | - H Hamanoue
- Department of Clinical Genetics, Yokohama City University Hospital, Yokohama, Japan
| | - H Uemura
- Department of Urology and Renal Transplantation, Yokohama City University Medical Center, Yokohama, Japan
| | - Y Yumura
- Department of Urology, Reproduction Center, Yokohama City University Medical Center, Yokohama, Japan
| |
Collapse
|
24
|
Takahashi T, Uemura H, Noto T, Shinozuka T, Kinoshita H, Matsuyama M, Suzuki S, Osamura Y, Oogushi Y, Hinohara S. Checkup Interval and Cancers in Automated Multiphasic Health Testing and Services. Methods Inf Med 2018. [DOI: 10.1055/s-0038-1634917] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/17/2022]
Abstract
Abstract:The purpose of this study was to disclose which types of cancer and how many persons with cancer were detected among the AMHTS examinees of our AMHTS center by using the hospital information retrieval system, and to study the relationship between cancer and the number of examinees, checkup intervals, and frequency in AMHTS. The examinees who had checkups more than twice were divided into three groups based on their checkup intervals: within one year, one to two years, and over two years. The relationship between cancer ratios and checkup intervals was evaluated in each group of examinees. In those having checkups within one year and from one to two years the cancer rate was 2.9 patients per 1,000 persons. However, in those having checkups after a two-year period or longer, the cancer rate was 4.3, clearly greater than the rate of the other two groups.
Collapse
|
25
|
Otaki N, Tanino N, Yokoro M, Yano M, Akita M, Uemura H, Maeda M, Fukuo K. Relationship between Economic Security and Self-Rated Health in Elderly Japanese Residents Living Alone. J Nutr Health Aging 2018; 22:695-699. [PMID: 29806858 DOI: 10.1007/s12603-017-0994-0] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
Abstract
OBJECTIVES The purpose of this study was to assess the relationship between economic security and self-rated health for elderly Japanese residents living alone. DESIGN A secondary analysis of a cross-sectional study. SETTING N City, H. Prefecture, Japan. PARTICIPANTS Survey questionnaires were distributed to 2,985 elderly residents living alone, aged ≥70 years, of which, 1,939 (65.0%) were returned and treated as valid responses. MEASUREMENTS The survey included questions about gender, age, number of years spent in N City, self-rated health, economic security, number of years spent living alone, reason for living alone, life satisfaction, cooking frequency, frequency of seeing a doctor, long-term care service usage, as well as whether they enjoyed their lives, participated in social organizations. RESULTS Of the respondents, 1,563 (80.6%) reported that they were economically secure, and 376 (19.4%) responded that they were insecure. The odds ratio predicting poor self-rated health for the economically insecure participants was significantly high (odds ratio: 3.19, 95%, Confidence Interval (CI): 2.53-4.02, and P < 0.001). Similarly, the adjusted odds ratio for poor self-rated health was significantly high for the economically insecure participants in multivariate analyses controlling for factors such as age, gender, cooking frequency, and social participation (adjusted odds ratio: 2.21, 95%, CI: 1.70-2.88, and P < 0.001). Furthermore, a similar trend was observed in stratified analyses based on gender and age groups. CONCLUSION Economic security predicted self-rated health independently of confounders, including social participation and cooking frequency, among the elderly Japanese living alone in communities.
Collapse
Affiliation(s)
- N Otaki
- Keisuke Fukuo, Department of Food Sciences and Nutrition, School of Human Environmental Sciences, Mukogawa Women's University, 6-46 Ikebiraki-cho, Nishinomiya, Hyogo 663-8558, Japan, Tel and Fax: +81-798-45-9922,
| | | | | | | | | | | | | | | |
Collapse
|
26
|
Uemura H, Kosaka T, Sumitomo M, Harada K, Sugimoto M, Hayashi N, Yoshimura K, Fukasawa S, Ecstein-Fraisse E, Sunaga Y, Oya M. Cabazitaxel plus prednisolone with primary prophylaxis with pegfilgrastim (PEG) in Japanese patients with metastatic castration-resistant prostate cancer: An open label prospective phase 2 study. Ann Oncol 2017. [DOI: 10.1093/annonc/mdx676.018] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
27
|
Matsubara N, Naito Y, Sasaki M, Yamamoto N, Takahashi S, Uemura H, Doi T. Phase I expansion cohort of TAS-115, a novel oral MET/VEGFR/FMS inhibitor, for castration-resistant prostate cancer patients (CRPC pts) with bone metastases. Ann Oncol 2017. [DOI: 10.1093/annonc/mdx370.013] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
28
|
|
29
|
Miyoshi Y, Uemura H, Suzuki K, Shibata Y, Honma S, Harada M, Kubota Y. High serum dihydrotestosterone examined by ultrasensitive LC-MS/MS as a predictor of benign prostatic hyperplasia or Gleason score 6 cancer in men with prostate-specific antigen levels of 3-10 ng/mL. Andrology 2016; 5:262-267. [PMID: 27813361 DOI: 10.1111/andr.12294] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/18/2016] [Revised: 09/03/2016] [Accepted: 09/12/2016] [Indexed: 11/30/2022]
Abstract
There has been no consensus on the role of serum androgen concentrations in prostate cancer detection in men with prostate-specific antigen levels of 3-10 ng/mL. In this study, testosterone and dihydrotestosterone concentrations in blood were examined by a newly developed method using ultrasensitive liquid chromatography with two serially linked mass spectrometers (LC-MS/MS). We investigated the correlation between serum androgen levels and Gleason scores at biopsy. We analyzed data of 157 men with a total prostate-specific antigen range of 3-10 ng/mL who underwent initial systematic prostate needle biopsy for suspected prostate cancer between April 2000 and July 2003. Peripheral blood testosterone and dihydrotestosterone concentrations were determined by LC-MS/MS. Blood levels of testosterone and dihydrotestosterone were compared with pathological findings by multivariate analyses. Median values of prostate-specific antigen and prostate volume measured by ultrasound were 5.7 ng/mL and 31.4 cm3 , respectively. Benign prostatic hyperplasia was diagnosed in 97 patients (61.8%), and prostate cancer was diagnosed in 60 (38.2%) patients, including 31 (19.7%) patients with a Gleason score of 6 and 29 (18.5%) patients with a Gleason score of 7-10. Median values of testosterone and dihydrotestosterone in blood were 3798.7 and 371.7 pg/mL, respectively. There was a strong correlation between serum testosterone and dihydrotestosterone. In multivariate analysis, age, prostate volume, and serum dihydrotestosterone were significant predictors of benign prostatic hyperplasia or prostate cancer with a Gleason score of 6. The area under the receiver operating characteristics curve for age, prostate volume, and serum dihydrotestosterone were 0.67, 0.67, and 0.67, respectively . We confirmed that high dihydrotestosterone blood levels can predict benign prostatic hyperplasia or prostate cancer with a Gleason score of 6 in men with prostate-specific antigen levels of 3-10 ng/mL.
Collapse
Affiliation(s)
- Y Miyoshi
- Department of Urology, Yokohama City University Graduate School of Medicine, Yokohama, Japan.,Department of Urology and Renal Transplantation, Yokohama City University Medical Center, Yokohama, Japan
| | - H Uemura
- Department of Urology, Yokohama City University Graduate School of Medicine, Yokohama, Japan.,Department of Urology and Renal Transplantation, Yokohama City University Medical Center, Yokohama, Japan
| | - K Suzuki
- Department of Urology, Gunma University Graduate School of Medicine, Maebashi, Japan
| | - Y Shibata
- Department of Urology, Gunma University Graduate School of Medicine, Maebashi, Japan
| | - S Honma
- ASKA Pharma Medical Co. Ltd., Kawasaki, Japan
| | - M Harada
- Department of Urology and Pathology, Kanagawa Cancer Center, Yokohama, Japan
| | - Y Kubota
- Department of Urology, Yokohama City University Graduate School of Medicine, Yokohama, Japan
| |
Collapse
|
30
|
Teranishi J, Hattori Y, Mochizuki T, Kawahara T, Makiyama K, Uemura H. Effective Treatment With Everolimus for Recurrent Granulomatous Interstitial Nephritis in a Renal Transplant Recipient: A Case Report. Transplant Proc 2016; 48:946-8. [PMID: 27234775 DOI: 10.1016/j.transproceed.2016.01.034] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/07/2015] [Accepted: 01/14/2016] [Indexed: 10/21/2022]
Abstract
BACKGROUND Granulomatous interstitial nephritis (GIN) is a rare renal disease, and its etiology remains unknown. We report recurrent GIN in renal allograft successfully treated with everolimus (EVR). CASE REPORT A 22-year-old man with GIN received a kidney from his mother. On follow-up 8 months later, his serum creatinine level was increased, from 1.3 mg/dL to 1.7 mg/dL, and he had microhematuria and proteinuria. A protocol graft biopsy at 1 year after transplantation showed epithelioid granuloma with multinucleated giant cells. He received steroid pulse therapy for recurrent GIN twice, but he developed allograft dysfunction, hematuria, and proteinuria. EVR was started in combination with maintenance immunosuppressants at 28 months after transplantation. Thereafter, the serum creatinine level decreased, from 2.1 mg/dL to 1.6 mg/dL, and microhematuria and proteinuria were stable despite reduction of steroid dose. CONCLUSIONS Maintenance immunosuppressive therapy combined with EVR may be effective for the recurrence of idiopathic GIN in renal allograft.
Collapse
Affiliation(s)
- J Teranishi
- Department of Urology and Renal Transplantation, Yokohama City University Medical Center, Kanagawa, Japan.
| | - Y Hattori
- Department of Urology and Renal Transplantation, Yokohama City University Medical Center, Kanagawa, Japan
| | - T Mochizuki
- Department of Urology and Renal Transplantation, Yokohama City University Medical Center, Kanagawa, Japan
| | - T Kawahara
- Department of Urology and Renal Transplantation, Yokohama City University Medical Center, Kanagawa, Japan
| | - K Makiyama
- Department of Urology, Yokohama City University Graduate School of Medicine, Kanagawa, Japan
| | - H Uemura
- Department of Urology and Renal Transplantation, Yokohama City University Medical Center, Kanagawa, Japan
| |
Collapse
|
31
|
Yada H, Ijiri Y, Uemura H, Tomioka Y, Okamoto H. Enhancement of Photoinduced Charge-Order Melting via Anisotropy Control by Double-Pulse Excitation in Perovskite Manganites: Pr_{0.6}Ca_{0.4}MnO_{3}. Phys Rev Lett 2016; 116:076402. [PMID: 26943548 DOI: 10.1103/physrevlett.116.076402] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Received: 12/22/2015] [Indexed: 06/05/2023]
Abstract
To control the efficiency of photoinduced charge-order melting in perovskite manganites, we performed femtosecond pump-probe spectroscopy using double-pulse excitation on Pr_{0.6}Ca_{0.4}MnO_{3}. The results revealed that the transfer of the spectral weight from the near-infrared to infrared region by the second pump pulse is considerably enhanced by the first pump pulse and that the suppression of crystal anisotropy, that is, the decrease of long-range lattice deformations due to the charge order by the first pump pulse is a key factor to enhance the charge-order melting. This double-pulse excitation method can be applied to various photoinduced transitions in complex materials with electronic and structural instabilities.
Collapse
Affiliation(s)
- H Yada
- Department of Advanced Materials Science, University of Tokyo, Kashiwa, Chiba 277-8561, Japan
| | - Y Ijiri
- Department of Advanced Materials Science, University of Tokyo, Kashiwa, Chiba 277-8561, Japan
| | - H Uemura
- Department of Advanced Materials Science, University of Tokyo, Kashiwa, Chiba 277-8561, Japan
| | - Y Tomioka
- National Institute of Advanced Industrial Science and Technology (AIST), Tsukuba, Ibaraki 305-8561, Japan
| | - H Okamoto
- Department of Advanced Materials Science, University of Tokyo, Kashiwa, Chiba 277-8561, Japan
| |
Collapse
|
32
|
Yasui M, Yoneyama S, Uemura K, Kawahara T, Hattori Y, Teranishi JI, Ohta JI, Yokomizo Y, Masahiro Y, Masataka T, Uemura H, Miyoshi Y. 245P Predictive factor of metastatic castration-resistant prostate cancer patients' poor response to secondary alternative antiandrogen therapy with flutamide. Ann Oncol 2015. [DOI: 10.1093/annonc/mdv524.10] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
|
33
|
Uemura H, Ye D, Wu TL, Lee JY, Chong Y, Razack A, Pripatnanont C, Chiong E, Lau W, Kanesvaran R, Li C, Rawal S, Tongaonkar H, Pu YS, Santingamkun A, Lojanapiwat B, Liang H, Mah K, van Kooten Losio M, Liu Y. 266TiP A multicenter, prospective, longitudinal registry of prostate cancer in Asia. Ann Oncol 2015. [DOI: 10.1093/annonc/mdv524.30] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
34
|
Diamantopoulos NP, Hayashi M, Yoshida Y, Maruta A, Maruyama R, Kuwaki N, Takenaga K, Uemura H, Matsuo S, Kitayama K. Mode-selective optical packet switching in mode-division multiplexing networks. Opt Express 2015; 23:23660-23666. [PMID: 26368463 DOI: 10.1364/oe.23.023660] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 06/05/2023]
Abstract
A novel mode-selective optical packet switching, based on mode-multiplexers/demultiplexers and multi-port optical micro-electro-mechanical systems (MEMS) switches, has been proposed and experimentally demonstrated. The experimental demonstration was performed using the LP(01), LP(11a) and LP(11b) modes of a 30-km long mode-division multiplexed few-mode fiber link, utilizing 40 Gb/s, 16-QAM signals.
Collapse
|
35
|
Uemura K, Miyoshi Y, Yoneyama S, Hattori Y, Teranishi J, Takebayashi S, Uemura H, Yao M. 410 Prognostic value of computer-aided diagnosis system for bone scan among men with docetaxel treatment for metastatic castration-resistance prostate cancer. Eur J Cancer 2015. [DOI: 10.1016/s0959-8049(16)30244-1] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/22/2022]
|
36
|
Ota I, Masui T, Mikami S, Uemura H, Kanno M, Kitahara T. 2816 Snail-induced EMT promotes the properties of cancer stem cells in head and neck cancer cells. Eur J Cancer 2015. [DOI: 10.1016/s0959-8049(16)31559-3] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
|
37
|
Yoneyama S, Miyoshi Y, Moriyama M, Uemura K, Takebayashi S, Uemura H, Yao M. 2524 Prognostic value of bone scan index (BSI) using computer-aided diagnosis system for bone scans in hormone-naive prostate cancer patients with bone metastases. Eur J Cancer 2015. [DOI: 10.1016/s0959-8049(16)31343-0] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/22/2022]
|
38
|
Hayashi N, Uemura H, Makiyama K, Nakaigawa N, Yao M, Koike I, Mukai Y. 2515 Ten-year outcomes of treatment for localized prostate cancer in a single institution; comparison of radical prostatectomy vs radiation therapy Propensity Score Matching Analysis. Eur J Cancer 2015. [DOI: 10.1016/s0959-8049(16)31335-1] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/25/2022]
|
39
|
Tani A, Yamamoto S, Maegawa M, Kunimi K, Matsui S, Keyama K, Kato T, Uemura H, Kuwahara A, Matsuzaki T, Yasui T, Kamada M, Soeki T, Sata M, Irahara M. Arterial stiffness is increased in young women with endometriosis. J OBSTET GYNAECOL 2014; 35:711-5. [PMID: 25543526 DOI: 10.3109/01443615.2014.992871] [Citation(s) in RCA: 15] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022]
Abstract
Endometriosis is a chronic gynaecological disorder that is accompanied by inflammation and oxidative stress. Atherosclerosis has a long subclinical progression in arteries of children and young adults decades before overt clinical manifestations of the disease. In this study, we determined arterial stiffness by measuring brachial-ankle pulse wave velocity (baPWV) in women with endometriosis to assess the presence of subclinical atherosclerosis. We also measured markers of inflammation and oxidative stress in women with endometriosis. baPWV in women with endometriosis aged over 30 years was significantly higher than that in women without endometriosis aged over 30 years (p < 0.05), but not in women aged less than 30. Serum high-sensitivity C-reactive protein level in women with endometriosis was significantly higher than that in controls (p < 0.05). Young women with endometriosis show significantly increased arterial stiffness, suggesting that women with endometriosis need to be cautious of the future onset of atherosclerosis.
Collapse
Affiliation(s)
- A Tani
- a Department of Obstetrics and Gynecology , Institute of Health Biosciences, The University of Tokushima Graduate School , Tokushima , Japan
| | - S Yamamoto
- a Department of Obstetrics and Gynecology , Institute of Health Biosciences, The University of Tokushima Graduate School , Tokushima , Japan
| | - M Maegawa
- b Department of Obstetrics and Gynecology , Tokushima Prefectural Central Hospital , Tokushima , Japan
| | - K Kunimi
- a Department of Obstetrics and Gynecology , Institute of Health Biosciences, The University of Tokushima Graduate School , Tokushima , Japan
| | - S Matsui
- a Department of Obstetrics and Gynecology , Institute of Health Biosciences, The University of Tokushima Graduate School , Tokushima , Japan
| | - K Keyama
- a Department of Obstetrics and Gynecology , Institute of Health Biosciences, The University of Tokushima Graduate School , Tokushima , Japan
| | - T Kato
- a Department of Obstetrics and Gynecology , Institute of Health Biosciences, The University of Tokushima Graduate School , Tokushima , Japan
| | - H Uemura
- c Department of Preventive Medicine , Institute of Health Biosciences, The University of Tokushima Graduate School , Tokushima , Japan
| | - A Kuwahara
- a Department of Obstetrics and Gynecology , Institute of Health Biosciences, The University of Tokushima Graduate School , Tokushima , Japan
| | - T Matsuzaki
- a Department of Obstetrics and Gynecology , Institute of Health Biosciences, The University of Tokushima Graduate School , Tokushima , Japan
| | - T Yasui
- d Department of Reproductive Technology , Institute of Health Biosciences, The University of Tokushima Graduate School , Tokushima , Japan
| | - M Kamada
- e Department of Obstetrics and Gynecology , Shikoku Central Hospital of the Mutual Aid Association of Public School Teachers , Ehime , Japan
| | - T Soeki
- f Department of Cardiovascular Medicine , Institute of Health Bioscience, The University of Tokushima Graduate School , Tokushima , Japan
| | - M Sata
- f Department of Cardiovascular Medicine , Institute of Health Bioscience, The University of Tokushima Graduate School , Tokushima , Japan
| | - M Irahara
- a Department of Obstetrics and Gynecology , Institute of Health Biosciences, The University of Tokushima Graduate School , Tokushima , Japan
| |
Collapse
|
40
|
Ishii T, Yasuda M, Saito Y, Mori Y, Hayashi T, Uemura H, Nose K, Nishioka T. Examination of the effect of changing to azilsartan from candesartan in renal transplant patients. Transplant Proc 2014; 46:492-5. [PMID: 24655997 DOI: 10.1016/j.transproceed.2013.11.018] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/26/2013] [Accepted: 11/06/2013] [Indexed: 11/17/2022]
Abstract
BACKGROUND Azilsartan, an angiotensin receptor blocker (ARB), was administered to renal transplant recipients to investigate the safety and antihypertensive effect in addition to its ARB-characteristic organ-protective effect. METHODS The subjects were 20 patients (18 males, 2 females; baseline serum creatinine 2.39 ± 1.33 mg/dL) responding poorly to candesartan, who suffered albuminuria (>0.3 g/g creatinine) and hypertension (>140/90 mm Hg) following renal transplantation. Three months after candesartan was switched to azilsartan 20 mg/d, blood pressure, creatinine-corrected urinary albumin excretion, urinary L-type acid binding protein, urinary 8-hydroxydeoxyguano-sine, serum creatinine, and estimated glomerular filtration rate were evaluated. Thirteen patients received cyclosporine (65.0%) and 7 received tacrolimus (35.0%). Another hypertensive (calcium antagonist) agent was combined in 7 (35.0%). RESULTS Systolic blood pressure significantly decreased from 139.5 mm Hg (baseline) from 128.7 mm Hg (at 3 months), whereas no significant changes were observed for diastolic blood pressure. The percentage of patients achieving the target level of antihypertensive effect (blood pressure < 130/80 mm Hg) significantly improved from 30.0% (baseline) to 70.0% (at 3 months). No significant changes were observed in renal graft function, oxidative stress marker level, or biochemical examination findings. CONCLUSION Sufficient antihypertensive effect was demonstrated soon after switching to azilsartan. However, no significant change was found in renal damage markers. Long-term study must be conducted to confirm the protective effect azilsartan on the transplanted kidney, as found with candesartan. The safety of azilsartan was demonstrated. If the transplanted kidney protection is demonstrated, this drug is expected to contribute to the improved long-term prognosis of renal transplant recipients.
Collapse
Affiliation(s)
- T Ishii
- Department of Urology, Kinki University Faculty of Medicine, Osaka-Sayama, Japan.
| | - M Yasuda
- Department of Urology, Kinki University Faculty of Medicine, Osaka-Sayama, Japan
| | - Y Saito
- Department of Urology, Kinki University Faculty of Medicine, Osaka-Sayama, Japan
| | - Y Mori
- Department of Urology, Kinki University Faculty of Medicine, Osaka-Sayama, Japan
| | - T Hayashi
- Department of Urology, Kinki University Faculty of Medicine, Osaka-Sayama, Japan
| | - H Uemura
- Department of Urology, Kinki University Faculty of Medicine, Osaka-Sayama, Japan
| | - K Nose
- Department of Urology, Sakai Hospital, Kinki University Faculty of Medicine, Sakai, Japan
| | - T Nishioka
- Department of Urology, Sakai Hospital, Kinki University Faculty of Medicine, Sakai, Japan
| |
Collapse
|
41
|
Miyoshi Y, Umemoto S, Uemura H, Shibata Y, Sakamaki K, Honma S, Suzuki K, Kubota Y. High Testosterone Levels in Prostate Tissue Obtained By Needle Biopsy Correlate with Poor Prognosis Factors in Prostate Cancer Patients. Ann Oncol 2014. [DOI: 10.1093/annonc/mdu336.28] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
42
|
Kutsuna S, Kato Y, Takasaki T, Moi ML, Kotaki A, Uemura H, Matono T, Fujiya Y, Mawatari M, Takeshita N, Hayakawa K, Kanagawa S, Ohmagari N. Two cases of Zika fever imported from French Polynesia to Japan, December 2013 to January 2014. Euro Surveill 2014; 19. [DOI: 10.2807/1560-7917.es2014.19.4.20683] [Citation(s) in RCA: 110] [Impact Index Per Article: 11.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
We present two cases of imported Zika fever to Japan, in travellers returning from French Polynesia, where an outbreak due to Zika virus (ZIKV) is ongoing since week 41 of 2013. This report serves to raise awareness among healthcare professionals, that the differential diagnosis of febrile and subfebrile patients with rash should include ZIKV infection, especially in patients returning from areas affected by this virus.
Collapse
Affiliation(s)
- S Kutsuna
- National Center for Global health and Medicine, Disease Control and Prevention Center, Tokyo, Japan
| | - Y Kato
- National Center for Global health and Medicine, Disease Control and Prevention Center, Tokyo, Japan
| | - T Takasaki
- Department of Virology 1, National Institute of Infectious Diseases, Shinjukuku, Tokyo, Japan
| | - M L Moi
- Department of Virology 1, National Institute of Infectious Diseases, Shinjukuku, Tokyo, Japan
| | - A Kotaki
- Department of Virology 1, National Institute of Infectious Diseases, Shinjukuku, Tokyo, Japan
| | - H Uemura
- National Center for Global health and Medicine, Disease Control and Prevention Center, Tokyo, Japan
| | - T Matono
- National Center for Global health and Medicine, Disease Control and Prevention Center, Tokyo, Japan
| | - Y Fujiya
- National Center for Global health and Medicine, Disease Control and Prevention Center, Tokyo, Japan
| | - M Mawatari
- National Center for Global health and Medicine, Disease Control and Prevention Center, Tokyo, Japan
| | - N Takeshita
- National Center for Global health and Medicine, Disease Control and Prevention Center, Tokyo, Japan
| | - K Hayakawa
- National Center for Global health and Medicine, Disease Control and Prevention Center, Tokyo, Japan
| | - S Kanagawa
- National Center for Global health and Medicine, Disease Control and Prevention Center, Tokyo, Japan
| | - N Ohmagari
- National Center for Global health and Medicine, Disease Control and Prevention Center, Tokyo, Japan
| |
Collapse
|
43
|
Matsui S, Yasui T, Tani A, Kato T, Uemura H, Kuwahara A, Matsuzaki T, Arisawa K, Irahara M. Effect of ultra-low-dose estradiol and dydrogesterone on arterial stiffness in postmenopausal women. Climacteric 2013; 17:191-6. [DOI: 10.3109/13697137.2013.856399] [Citation(s) in RCA: 10] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/18/2022]
|
44
|
Uemura H, Katsuura-Kamano S, Yamaguchi M, Nakamoto M, Hiyoshi M, Arisawa K. Abundant daily non-sedentary activity is associated with reduced prevalence of metabolic syndrome and insulin resistance. J Endocrinol Invest 2013; 36:1069-75. [PMID: 23886980 DOI: 10.3275/9066] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/17/2022]
Abstract
BACKGROUND Non-exercise activity thermogenesis has recently drawn attention because of its potential to prevent weight gain. AIM This study evaluated the relationships between the duration of daily non-sedentary activities and the prevalence of metabolic syndrome and insulin resistance (IR) in the Japanese population. MATERIAL/SUBJECTS AND METHODS A total of 518 eligible subjects (380 men and 138 women) who attended the Tokushima Prefectural General Health Checkup Center and participated in the baseline survey of a cohort study conducted in Tokushima Prefecture, Japan were analyzed. Information about lifestyle characteristics including leisure-time exercise and daily non-exercise activities was obtained from a questionnaire. Logistic and multiple linear regression analyses were performed to evaluate the associations between the duration of daily non-exercise non-sedentary activities (beyond sitting) and prevalence of metabolic syndrome (and its components) and IR. RESULTS Subjects with longer duration of daily non-sedentary activities had significantly lower adjusted odds ratios for metabolic syndrome (p for trend =0.024), abdominal obesity (p for trend =0.023), and low HDLcholesterol levels (p for trend =0.002), after adjustment for sex, age, and other probable covariates including leisure-time exercise. Longer duration of daily non-sedentary activities was further associated with lower homeostasis model of assessment- IR (HOMA-IR) values (p for trend =0.009). CONCLUSIONS Our results suggest that abundant daily non-sedentary activity might be associated with a lower prevalence of metabolic syndrome, especially for the components of central obesity and low HDL-cholesterol levels, and with a lower prevalence of IR, independent of leisure-time exercise.
Collapse
Affiliation(s)
- H Uemura
- Department of Preventive Medicine, Institute of Health Biosciences, The University of Tokushima Graduate School, 3-18-15, Kuramoto- cho, Tokushima 770-8503, Japan.
| | | | | | | | | | | |
Collapse
|
45
|
Matsui S, Yasui T, Tani A, Kato T, Kunimi K, Uemura H, Kuwahara A, Matsuzaki T, Irahara M. Difference in the ratio of high-molecular weight (HMW) to total adiponectin and HMW adiponectin in late post-menopausal women. J Endocrinol Invest 2013; 36:982-5. [PMID: 23765418 DOI: 10.3275/9001] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 04/19/2023]
Abstract
OBJECTIVE High-molecular weight (HMW) isoform level and HMW ratio have been shown to be better predictors of insulin sensitivity and metabolic syndrome than total adiponectin level.We examined the changes in circulating levels of HMW adiponectin and ratios of HMW to total adiponectin in women during the menopausal transition. METHODS We conducted a cross-sectional study in 217 healthy women and divided them into 4 stages: 58 women in pre-menopausal, 69 women in perimenopausal, 62 women in early post-menopausal and 28 women in late post-menopausal phase. Serum levels of total adiponectin and HMW adiponectin were measured by an enzyme-linked immunosorbent assay. RESULTS In late post-menopausal women, HMW adiponectin level was significantly higher than that in peri-menopausal women and the HMW to total adiponectin ratio was significantly lower than that in early post-menopausal women. In peri-menopausal women, HMW adiponectin level was significantly lower than that in pre-menopausal women and HMW to total adiponectin ratio was significantly lower than the ratios in pre-menopausal and early post-menopausal women. CONCLUSION The ratio of HMW to total adiponectin is low in late post-menopausal women, though both levels of total and HMW adiponectin were high after menopause in our cross-sectional study.
Collapse
Affiliation(s)
- S Matsui
- Department of Obstetrics and Gynecology, Institute of Health Biosciences, The University of Tokushima Graduate School, 3-18-15 Kuramoto, Tokushima 770-8503, Japan.
| | | | | | | | | | | | | | | | | |
Collapse
|
46
|
Ntalarizou E, Dimopoulos K, Saeed I, Swan L, Uemura H. An unusual case of Ebstein anomaly in 72 year old woman. J Cardiothorac Surg 2013. [PMCID: PMC3846112 DOI: 10.1186/1749-8090-8-s1-p97] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/10/2022] Open
Affiliation(s)
- E Ntalarizou
- Congenital Heart Disease Surgery, Royal Brompton and Harefield NHS Foundation Trust, London, UK
| | - K Dimopoulos
- Cardiology Department, Royal Brompton and Harefield NHS Foundation Trust, London, UK
| | - I Saeed
- Congenital Heart Disease Surgery, Royal Brompton and Harefield NHS Foundation Trust, London, UK
| | - L Swan
- Adult Congenital Heart Disease Cardiology Department, Royal Brompton and Harefield NHS Foundation Trust, London, UK
| | - H Uemura
- Congenital Heart Disease Surgery, Royal Brompton and Harefield NHS Foundation Trust, London, UK
| |
Collapse
|
47
|
Uemura H, Hayakawa K, Hamada Y, Yamamoto K, Kutsuna S, Ujiie M, Takeshita N, Kato Y, Kanagawa S, Shimada K, Kirikae T, Ohmagari N. P324 Parvimonas micra as a causative organism of spondylodiscitis: A report of 3 cases. Int J Antimicrob Agents 2013. [DOI: 10.1016/s0924-8579(13)70565-x] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/26/2022]
|
48
|
Uemura H, Ou YC, Lim H, Tomita Y, Ueda T, Menon H, Chung J, Guo J, Tarazi J, Kim S, Naito S, Akaza H. Phase III AXIS Trial of Axitinib Versus Sorafenib in Patients with Metastatic Renal Cell Carcinoma: Asian Subgroup Analysis. Ann Oncol 2012. [DOI: 10.1093/annonc/mds496] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
49
|
Motzer R, Hutson T, Reeves J, Hawkins R, Guo J, Nathan P, Staehler M, de Souza P, Merchan J, Fife K, Jin J, Jones R, Uemura H, De Giorgi U, Harmenberg U, Wang J, Cella D, McCann L, Deen K, Choueiri T. Randomized, Open-Label, Phase III Trial Of Pazopanib Versus Sunitinib In First-Line Treatment Of Patients With Metastatic Renal Cell Carcinoma (MRCC): Results of the Comparz Trial. Ann Oncol 2012. [DOI: 10.1016/s0923-7534(20)34325-8] [Citation(s) in RCA: 31] [Impact Index Per Article: 2.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022] Open
|
50
|
Tao S, Ohtani N, Uchida R, Miyamoto T, Matsui Y, Yada H, Uemura H, Matsuzaki H, Uemura T, Takeya J, Okamoto H. Relaxation dynamics of photoexcited excitons in rubrene single crystals using femtosecond absorption spectroscopy. Phys Rev Lett 2012; 109:097403. [PMID: 23002882 DOI: 10.1103/physrevlett.109.097403] [Citation(s) in RCA: 8] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Received: 10/24/2011] [Revised: 04/06/2012] [Indexed: 06/01/2023]
Abstract
The relaxation dynamics of an exciton in rubrene was investigated by femtosecond absorption spectroscopy. Exciton relaxation to a self-trapped state occurs via the coherent oscillation with 78 cm(-1) due to a coupled mode of molecular deformations with phenyl-side-group motions and molecular displacements. From the temperature dependence of the decay time of excitons, the energy necessary for an exciton to escape from a self-trapped state is evaluated to be ~35 meV (~400 K). As a result, a self-trapped exciton is stable at low temperatures. At room temperature, excitons can escape from a self-trapped state and, subsequently, they are dissociated to charged species. The exciton dissociation mechanism is discussed on the basis of the results.
Collapse
Affiliation(s)
- S Tao
- Department of Advanced Materials Science, University of Tokyo, Kashiwa, Chiba, Japan
| | | | | | | | | | | | | | | | | | | | | |
Collapse
|